(RTTNews) - Bristol-Myers Squibb Co. (BMY) and Eisai Co., Ltd. have reached a strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate ...
a CI calculations: ORR, DCR—Clopper-Pearson's exact method; PFS, OS—Kaplan-Meier estimate and Greenwood Formula. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract ...
Exton, PA, March 2, 2009 -- Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal ...
Morphotek Announces Initiation of a Phase I Study for MORAb-028, an IgM-Type Monoclonal Antibody, in Patients with Advanced Melanoma EXTON, Pa., Aug 16, 2010 (BUSINESS WIRE) -- Morphotek(R),Inc., a ...
Clinical Study Seeks to Evaluate MORAb-004 Plus the Standard of Care for Extending Progression-Free Survival of Patients with Metastatic Soft Tissue Sarcoma MORAb-004 is thought to function as an ...
Genomic characterization of vulvar squamous cell carcinoma to reveal differential gene expression based on clinical outcome. The distribution of HPV subtype in vulvar intraepithelial neoplasia and the ...
Address H C PATIL BUILDING , NEAR BUS STAND, MORAB , DHARWAR DISTRICT , MORAB , 580112 Buy Bank of Baroda; target of Rs 275: Sharekhan Buy Bank of Baroda; target of Rs 270: Prabhudas Lilladher Trade ...
Disclaimer: The information provided herein, including PIN code and post-office-related details, is for information purposes only. While publishing PIN codes and other associated information, NDTV has ...
Under the agreement, Eisai and Bristol Myers Squibb will jointly develop and commercialize MORAb-202 in the following collaboration territories: Japan; China; countries in the Asia-Pacific region*; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results